Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Classical Hodgkin's Lymphoma Clear all
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

NCT00967369
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Bortezomib, Carboplatin, Etoposide, Ifosfamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 1 Interventional

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

NCT02153580
View directory record Official record
Conditions
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide, Etoposide, Fludarabine Phosphate
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT04318080
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Tislelizumab
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Detroit, Michigan • Knoxville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03776864
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Pembrolizumab, Umbralisib
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

NCT00722865
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Avastin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 17, 2026, 5:16 AM EDT
Withdrawn Phase 2 Interventional

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

NCT04138875
View directory record Official record
Conditions
PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
Interventions
Rituximab, Brentuximab Vedotin, Bendamustine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT02332668
View directory record Official record
Conditions
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Interventions
Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

NCT01022996
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
16
States / cities
Los Angeles, California • Greenwood Village, Colorado • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 2 Interventional

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

NCT07021989
View directory record Official record
Conditions
Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine, Vinorelbine, Liposomal Doxorubicin, Foresight CLARITY™ LDT, Pegfilgrastim, Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)
Drug · Radiation · Device + 1 more
Lead sponsor
Michael Spinner, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
6
States / cities
Davis, California • Fresno, California • Irvine, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 1 Interventional

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

NCT04288726
View directory record Official record
Conditions
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Interventions
CD30.CAR-EBVST cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

NCT05723055
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Axatilimab, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

NCT00439361
View directory record Official record
Conditions
Hodgkin Lymphoma, Lymphoma
Interventions
Bortezomib, Carboplatin, Etoposide, Ifosfamide, Mesna
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2012 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

NCT01900496
View directory record Official record
Conditions
Lymphoma
Interventions
Brentuximab vedotin, Rituximab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
16 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma

NCT06164275
View directory record Official record
Conditions
Classic Hodgkin Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography, Multigated Acquisition Scan, Pembrolizumab, Positron Emission Tomography, Vinblastine
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Geneva, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT02665650
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
AFM13, Pembrolizumab
Biological
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 17, 2026, 5:16 AM EDT
Completed No phase listed Observational

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

NCT03200977
View directory record Official record
Conditions
Lymphoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Lawrenceville, New Jersey • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

NCT03407144
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
pembrolizumab, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, etoposide, Radiotherapy (RT)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
3 Years to 25 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

NCT00117988
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

NCT04074746
View directory record Official record
Conditions
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Genetically Engineered Lymphocyte Therapy
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Early Phase 1 Interventional

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

NCT04134325
View directory record Official record
Conditions
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Pembrolizumab
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

NCT07275216
View directory record Official record
Conditions
Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Echocardiography Test, Gemcitabine, Pembrolizumab, Physical Performance Testing, Positron Emission Tomography, Pulmonary Function Test
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

NCT00540007
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Lenalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
St Louis, Missouri • Hackensack, New Jersey • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

NCT02927769
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Nivolumab, brentuximab vedotin, bendamustine
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 30 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 17, 2026, 5:16 AM EDT